

## Bod delivers record fourth quarter revenue of \$2.5m

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

### CAPITAL STRUCTURE

ASX code **BDA**  
 Shares on issue 91.4m  
 Market Capitalisation ~\$24.7m

### BOARD & MANAGEMENT

Mr Mark Masterson  
 Non-Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Akash Bedi  
 Non-Executive Director

Mr George Livery  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O'Loughlin  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

### CONTACT

Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

- Q4 revenue accounts for ~42% of FY2020's current total revenue of \$5.92m<sup>i</sup>
- Outlines a 100% increase on Q3 FY2020 revenue (Q3 FY 2020: \$1.25m)
- Record result driven by domestic and international growth in medicinal cannabis and CBD and hemp product divisions
- Bod is exceptionally well funded with ~\$6.3m cash at bank and no debt
- Revenue growth expected to continue in FY2021

**Sydney, Australia – 2 July 2020:** Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited ("Bod", the "Company") (ASX: BDA) is pleased to report record revenue of \$2.5m for quarter ending 30 June 2020 (Q4 FY2020) which accounts for ~42% of the total revenue currently booked for FY2020 (FY2020: \$6.0m). Quarterly revenue and cumulative revenue for FY2020 is illustrated in the chart below.

This is an excellent result for Bod and it clearly demonstrates that the investment the Company has made during the year in its medicinal cannabis and CBD and hemp consumer products divisions is now generating growing, diversified and sustainable revenue streams.

**CEO Jo Patterson said:** *"This is an exceptional result for Bod. In the last year, we have invested considerably in building our two core divisions and this hard work is now paying off. Revenue growth from the last two quarters clearly reflects this."*

*"Demand for our innovative products is now translating into sustainable revenue streams and we are confident that this will only increase as we generate more sales from existing products, introduce new products and enter new markets. As such, we anticipate with some confidence that revenue will continue to track up during FY2021 and beyond. Bod is very well-primed for growth."*

Bod advises that FY2020 revenue may increase further, following final calculation of royalty payments receivable from Health & Happiness Group International Holdings Limited (H&H Group, HKSE: 1112) however these adjustments are not anticipated to be material. The Company's Appendix 4C and associated quarterly activities report will be lodged towards the end of this month. A number of key operational developments including new product launches, R&D initiatives and new partnerships are expected to be reported in the interim.




Chart: Total revenue achieved per period and cumulative FY2020 revenue growth

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538

---

<sup>i</sup> Denotes revenue recognised to date. Total FY2020 revenue is currently unaudited and may change following the calculation of royalties from Health & Happiness Group International Holdings Limited (H&H Group, HKSE: 1112) and other income.